Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.53
(3.53%)
CNY 20.53
(3.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.05 Billion CNY | -312.26% |
| 2022 | 168.09 Million CNY | -50.42% |
| 2021 | 378.5 Million CNY | -8.89% |
| 2020 | 412.64 Million CNY | 13.11% |
| 2019 | 360.04 Million CNY | 10.33% |
| 2018 | 258.94 Million CNY | 6.85% |
| 2017 | 310.91 Million CNY | 15.85% |
| 2016 | 269.57 Million CNY | 8.18% |
| 2015 | 250.01 Million CNY | 19.48% |
| 2014 | 211.27 Million CNY | 23.79% |
| 2013 | 169.08 Million CNY | 21.48% |
| 2012 | 137.14 Million CNY | 37.13% |
| 2011 | 101.25 Million CNY | 20.27% |
| 2010 | 83.79 Million CNY | 52.75% |
| 2009 | 53.61 Million CNY | 139.09% |
| 2008 | 22.97 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 38.65 Million CNY | 197.2% |
| 2024 Q3 | 42.12 Million CNY | 8.99% |
| 2024 Q1 | -39.76 Million CNY | 95.06% |
| 2023 Q1 | 27.24 Million CNY | 225.2% |
| 2023 Q2 | -91.8 Million CNY | -436.92% |
| 2023 FY | - CNY | -312.26% |
| 2023 Q3 | -144.05 Million CNY | -56.92% |
| 2023 Q4 | -267.43 Million CNY | -85.65% |
| 2022 Q3 | 29.71 Million CNY | -56.92% |
| 2022 FY | - CNY | -50.42% |
| 2022 Q4 | -21.76 Million CNY | -173.23% |
| 2022 Q2 | 68.97 Million CNY | 24.93% |
| 2022 Q1 | 55.21 Million CNY | 9.27% |
| 2021 Q1 | 96.74 Million CNY | 10.22% |
| 2021 FY | - CNY | -8.89% |
| 2021 Q3 | 69.29 Million CNY | -36.41% |
| 2021 Q2 | 108.97 Million CNY | 12.65% |
| 2021 Q4 | 50.52 Million CNY | -27.09% |
| 2020 FY | - CNY | 13.11% |
| 2020 Q1 | 72.91 Million CNY | 11.16% |
| 2020 Q4 | 87.77 Million CNY | -15.22% |
| 2020 Q3 | 103.53 Million CNY | 4.53% |
| 2020 Q2 | 99.04 Million CNY | 35.85% |
| 2019 Q2 | 85.92 Million CNY | 15.61% |
| 2019 FY | - CNY | 10.33% |
| 2019 Q1 | 74.32 Million CNY | 0.78% |
| 2019 Q3 | 91.9 Million CNY | 6.96% |
| 2019 Q4 | 65.59 Million CNY | -28.63% |
| 2018 Q1 | 66.81 Million CNY | -28.99% |
| 2018 Q2 | 76.61 Million CNY | 14.68% |
| 2018 Q4 | 73.74 Million CNY | 1.52% |
| 2018 Q3 | 72.64 Million CNY | -5.19% |
| 2018 FY | - CNY | 6.85% |
| 2017 Q3 | 68.27 Million CNY | 15.09% |
| 2017 FY | - CNY | 15.85% |
| 2017 Q1 | 53.97 Million CNY | -42.89% |
| 2017 Q4 | 94.09 Million CNY | 37.82% |
| 2017 Q2 | 59.32 Million CNY | 9.9% |
| 2016 Q4 | 94.51 Million CNY | 109.88% |
| 2016 FY | - CNY | 8.18% |
| 2016 Q1 | 41.32 Million CNY | -59.62% |
| 2016 Q3 | 45.03 Million CNY | -22.03% |
| 2016 Q2 | 57.75 Million CNY | 39.75% |
| 2015 Q1 | 33.59 Million CNY | -62.36% |
| 2015 Q4 | 102.34 Million CNY | 176.73% |
| 2015 Q3 | 36.98 Million CNY | -31.51% |
| 2015 Q2 | 53.99 Million CNY | 60.7% |
| 2015 FY | - CNY | 19.48% |
| 2014 Q4 | 89.26 Million CNY | 233.09% |
| 2014 FY | - CNY | 23.79% |
| 2014 Q1 | 29.42 Million CNY | -53.19% |
| 2014 Q2 | 40.91 Million CNY | 39.02% |
| 2014 Q3 | 26.8 Million CNY | -34.5% |
| 2013 Q4 | 62.86 Million CNY | 201.91% |
| 2013 FY | - CNY | 21.48% |
| 2013 Q1 | 27.01 Million CNY | -55.29% |
| 2013 Q2 | 45.12 Million CNY | 67.02% |
| 2013 Q3 | 20.82 Million CNY | -53.85% |
| 2012 Q3 | 16.36 Million CNY | -43.44% |
| 2012 Q2 | 28.94 Million CNY | 33.11% |
| 2012 Q1 | 21.74 Million CNY | -16.27% |
| 2012 FY | - CNY | 37.13% |
| 2012 Q4 | 60.42 Million CNY | 269.16% |
| 2011 Q3 | 9.84 Million CNY | -73.91% |
| 2011 Q4 | 25.96 Million CNY | 163.73% |
| 2011 FY | - CNY | 20.27% |
| 2011 Q2 | 37.73 Million CNY | 72.57% |
| 2011 Q1 | 21.86 Million CNY | -6.74% |
| 2010 Q3 | 19.64 Million CNY | 0.0% |
| 2010 FY | - CNY | 52.75% |
| 2010 Q4 | 23.44 Million CNY | 19.38% |
| 2009 FY | - CNY | 139.09% |
| 2008 FY | - CNY | 0.0% |